Belle Mead, New Jersey 08502

  • Substance Abuse


The purpose of this research study is to determine whether Nexalin Trans-cranial Electrical Stimulation (TES) is a viable adjunctive treatment of substance use treatments.

Study summary:

A Randomized Controlled Trial with block randomization. Inpatient subjects actively seeking substance abuse treatment at the Carrier Clinic who are diagnosed with a substance use disorder, including alcohol use disorder, tobacco use disorder, polysubstance use disorder, or other substance use disorder.


Inclusion Criteria: 1. Be able to provide informed consent, assessed by the study clinician 2. Be able to speak, read and write fluently in English, assessed by the study clinician 3. Be committed to completion of the study. The subject will need to attest to availability for 10 to 15 treatments over a 5 to 8 day period for the treatment protocol. 4. Be adults over age 18 and under age 65 5. Be actively receiving substance use treatment for a substance use disorder Exclusion Criteria: 1. Pregnant or at risk of becoming pregnant 2. Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, might confound the interpretation of the study results, or put the person at undue risk



Primary Contact:

Principal Investigator
Michael R Grandner, PhD
University of Arizona

Backup Contact:


Location Contact:

Belle Mead, New Jersey 08502
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: June 22, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.